Company Update (NASDAQ:KERX): Keryx Biopharmaceuticals Announces Case Study Data of Auryxia® Presented at ASN’s Kidney Week

Keryx Biopharmaceuticals (NASDAQ:KERX) announced case study data, which showed that Auryxia® (ferric citrate) lowered and maintained serum phosphorus levels in chronic kidney disease (CKD) patients on dialysis. These data were presented in a poster presentation today at the American Society of Nephrology’s 2016 Kidney Week taking place in Chicago.

Auryxia (ferric citrate) is currently indicated for the control of serum phosphorus levels in patients with CKD on dialysis.

“Data from this poster at ASN provide the first real-world evidence of the effect of Auryxia in treating hyperphosphatemia in people on dialysis,” said John Neylan, M.D., chief medical officer of Keryx Biopharmaceuticals. “With Auryxia available again at pharmacies, we are pleased to be able to provide these data from the everyday practice setting that support Auryxia’s profile.” (Original Source)

Shares of Keryx are currently trading at $6.27, down $0.01, or -0.16%. KERX has a 1-year high of $7.80 and a 1-year low of $2.80. The stock’s 50-day moving average is $5.14 and its 200-day moving average is $5.53.

On the ratings front, KERX stock has been the subject of a number of recent research reports. In a report issued on November 11, FBR analyst Christopher James reiterated a Hold rating on KERX, with a price target of $7, which represents a potential upside of 11% from where the stock is currently trading. Separately, on November 9, Maxim’s Jason Kolbert reiterated a Hold rating on the stock .

According to, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Christopher James and Jason Kolbert have a yearly average loss of 6.8% and 14.3% respectively. James has a success rate of 36% and is ranked #4012 out of 4229 analysts, while Kolbert has a success rate of 28% and is ranked #4139.

Keryx Biopharmaceuticals, Inc. engages in the development and commercialization of medicines for the treatment of renal disease. Its products include phosphate-binding medicines, intravenous iron, and other medications. The company was founded in October 1998 and is headquartered in Boston, MA.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts